AstraZeneca joins Boehringer Ingelheim in capping out-of-pocket inhaler costs at $35

Just as in­sulin man­u­fac­tur­ers were pres­sured in­to cap­ping month­ly out-of-pock­et costs, in­haler man­u­fac­tur­ers are feel­ing the same heat. As­traZeneca on Mon­day joined with Boehringer In­gel­heim to cap the price of its block­buster in­halers at $35 per month.

Be­gin­ning on June 1, As­traZeneca’s four in­halers, in­clud­ing Sym­bi­cort and Air­supra, will be capped, ac­cord­ing to the com­pa­ny. As­traZeneca record­ed more than $2.3 bil­lion in Sym­bi­cort sales in 2023, but gener­ic com­pe­ti­tion en­tered the US mar­ket in the third quar­ter of last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.